Cannabinoids are being used in clinical trials in the US and other countries for indications other than the direct treatment of cancer.

..."You can find out the details about these trials by visiting http://www.cancer.gov/clinicaltrialsOpens new window or http://apps.who.int/trialsearch/Opens new window


http://www.cpmc.org/professionals/research/programs/science/cannabidiolarticles.html



Sean D. McAllister, Ph.D.
Email: Mcallis@cpmcri.org

Pierre Desprez, Ph.D.
Email: DesprePY@cpmcri.org

Publications
McAllister
SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C,
Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY.
Pathways mediating the effects of cannabidiol on the reduction of breast
cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011 Aug;129(1):37-47. Epub 2010 Sep 22.

McAllister
SD, Christian RT, Horowitz MP, Garcia A, Desprez P. Cannabidiol as a
novel inhibitor of Id-1 gene expression in aggressive breast cancer
cells. Molecular Cancer Therapeutics 6, 2921-2927, November 1,
2007.Opens new window

News Interview
Sean
McAllister and Pierre Desprez discussed their recently published
findings on cannabidiol inhibiting breast cancer progression in culture
on BBC News/Health and in the San Francisco Chronicle .
Use the key word cannabinoids. These sites are also a wonderful
resource for finding additional novel trials that focus on treating
cancer.

At this point, there is no clinical evidence
demonstrating cannabiniods/cannabis can slow cancer progression but the
preclinical data in culture and in mouse models of cancer show the
compounds could slow the progression of many types of cancer. There are
however multiple clinical studies with cancer patients that show that
cannabinoid compounds and cannabis can be used palliatively to reduce
nausea and pain, and increase appetite.

In preclinical models of
brain cancer, cannabinoids were most efficacious when given in
combination with temozolomide-a common first-line agent used to target
brain cancer. Based on the data, it would be expected that cannabinoids
would need to be combined with a first-line agent in order to see the
most efficacy in a clinical setting. Recent publications using
preclinical models suggest this type of enhancement of drug activity
occurs in other cancers when cannabinoids are combined with first-line
agents.

We targeted breast cancer cells that expressed high
amounts of the protein Id-1. CBD is highly effective at turning off
this specific gene that controls breast cancer metastasis. In addition
to directly controlling cancer metastasis, turning off Id-1 has also
lead to enhanced activity of first-line agents in preclinical models of
cancer.
References
Soroceanu L, Murase R, Limb
C...Desprez PY, McAllister SD. Id-1 is a key transcriptional regulator
of glioblastoma aggressiveness and a novel therapeutic target. Cancer
Res 2013;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012
Dec 13.


Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as
antitumour agents. Nature Reviews Cancer 12, 436-444 (June 2012) |
doi:10.1038/nrc3247Opens new window.

Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon
L. Cannabis in palliative medicine: improving care and reducing
opioid-related morbidity. Am J Hosp Palliat Care 2011;28:297-303Opens new window.

Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical
therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90-103Opens new window.


McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY.
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive
breast cancer cells. Mol Cancer Ther 2007;6:2921-7Opens new window.


McAllister SD, Murase R, Christian RT, et al. Pathways mediating the
effects of cannabidiol on the reduction of breast cancer cell
proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011;129:37-47Opens new window.


Hu H, Han HY, Wang YL, et al. The role of Id-1 in chemosensitivity and
epirubicin-induced apoptosis in bladder cancer cells. Oncol Rep
2009;21:1053-9Opens new window.


Ponz-Sarvise M, Nguewa PA, Pajares MJ, et al. Inhibitor of
differentiation-1 as a novel prognostic factor in NSCLC patients with
adenocarcinoma histology and its potential contribution to therapy
resistance. Clin Cancer Res 2011;17:4155-66Opens new window.

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells


\t\t\t\t\t\t\t\t\t

\t\t\t\t\t\t\t\t\t
\t\t\t\t\t\t\t\t


\t\t\t\t\t\t\t

\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\t\t\t\t\t\t\t\t
\t\t\t\t\t\t\t

\t\t\t\t\t\t\t


\t\t\t\t\t\t

\t\t\t\t\t\t
\t\t\t\t\t\t\t\t
\t\t\t\t\t\t
\t\t\t\t\t\t\t\t\t
\t\t\t\t\t\t\t\t\t\t